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Summary Civil society has been a driving force behind efforts to increase access to treatment in Thailand. A focus
on HIV medicines brought civil society and non-governmental and government actors together to ﬁght
for a single cause, creating a platform for joint action on practical issues to improve care for people with
HIV⁄AIDS (PHA) within the public health system. The Thai Network of People with HIV⁄AIDS, in
partnership with other actors, has provided concrete support for patients and for the health system as a
whole; its efforts have contributed signiﬁcantly to the availability of affordable generic medicines, early
treatment for opportunistic infections, and an informed and responsible approach towards antiretroviral
treatment that is critical to good adherence and treatment success. This change in perception of PHA
from ‘passive receiver’ to ‘co-provider’ of health care has led to improved acceptance and support within
the healthcare system. Today, most PHA in Thailand can access treatment, and efforts have shifted to
supporting care for excluded populations.
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Introduction
Since the 1970s, health professionals in Thailand have
played an important public role in health sector reform,
sometimes risking their professional positions but often
emerging with enhanced public standing (Bamber 1997). In
1985, civic groups joined their efforts by lobbying (initially
with little success) against increasingly restrictive patent
legislation for pharmaceuticals, which in their view limited
access to affordable medicines.
In 1998, civil society involvement in health advocacy
was reinforced with the establishment of the Thai
Network of People with HIV⁄AIDS (TNP+). Motivated
by a combination of despair in front of death, a strong
desire to help friends who fell ill, and anger at a system
that made life-saving medicines unaffordable for the
majority, people with HIV⁄AIDS (PHA) have developed
a central role in advocacy for improved access to AIDS
drugs and have also promoted a patient-centred
approach to HIV⁄AIDS care within the public health
sector. Their role is recognized by the Ministry of Public
Health as central to the successful expansion of
antiretroviral treatment through activities that encourage
community education, reduce discrimination, provide
peer support, and promote the right of government to
make and use affordable generic drugs (Kunaratanapruk
2004).
Treatment activism has brought civic groups (Table 1)
together to ﬁght for a single cause, creating a platform for
joint action on practical issues to improve care within the
public health system. We describe the main activities of
three groups over the last decade: AIDS ACCESS
Foundation, the TNP+ and Me ´decins Sans Frontie `res
(MSF). Their efforts have implicated PHA in treatment
activism and as co-providers of care within the public
health system.
This article, written by representatives of these three
groups, aims to complement recent analyses on the
engagement of non-governmental organizations (NGOs)
in the provision of HIV⁄AIDS care in Thailand (Lyttleton
et al. 2007; Tantivess & Walt 2008). The aim of
providing this participant-observer’s perspective over the
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of the process of policy change in Thailand. Such
perspectives have recently been noted as lacking in the
health policy literature, particular in relation to commu-
nity participation in health policy formulation (Gilson &
Raphaely 2008).
Context: government, civil society and HIV⁄AIDS in
Thailand
Thailand’s HIV epidemic began in 1984, with cases
initially conﬁned to perceived ‘high-risk’ groups: gay men,
then injecting drug users and then commercial sex workers.
Table 1 Civic groups promoting access to treatment in Thailand
Governmental actors
The Government Pharmaceutical Organization is a state enterprise formed in 1966 to provide affordable quality medicines for the public
health system. Ofﬁcials from its Research and Development Institute have, together with other health professionals, taken a public
stance on issues of access to medicines at some risk to their professional positions.
The Ofﬁce of Health Care Reform: In 1996, the Ministry of Public Health started a 3-year initiative to increase equity in access to health
care, with patient and community involvement. The initiative identiﬁed as major concerns lack of access and affordability of drugs for
HIV, both for opportunistic infections and antiretroviral therapy (Nitayarumphong 1996). MSF, TNP+ and ACCESS (see below)
co-operated in establishing a standard of prevention and treatment of opportunistic infections at district level.
The National Health Security Ofﬁce: The national health security scheme, promulgated in 2002, partially replaces three previous public
insurance schemes and also covers those who were previously uninsured. AIDS NGOs sit on the governing board, as required under the
1997 constitution (Towse et al. 2004).
Non-governmental groups established by health and other professionals
The Law Society, established in 1957, provides gratis defence of certain human rights cases, such as the legal challenge by PHA to
the patent on the antiretroviral drug didanosine.
The PDA, founded in 1974, provides a wide range of support for the rural poor. PDAs humorous and common sense approach has
contributed signiﬁcantly to HIV prevention efforts. In 2004, PDA obtained funding for antiretroviral treatment programmes,
implemented by MSF and the Ministry of Public Health, for ethnic minorities and migrant workers from Laos and Myanmar.
The Rural Doctors’ Society, founded in 1978 to support rural health services, supports public health initiatives such as the
formulation of a national drug policy, and acts as a watchdog to counter corruption and inappropriate administrative behaviour in
the health system (Wibulpolprasert & Pengpaibon 2003; Bamber 1997).
The Health and Development Foundation, founded in 1983, has developed expertise in pharmaceutical and patent regulations and
challenged antiretroviral patent applications and supported civil society negotiations in the US–Thailand FTAs.
The International Law Association of Thailand, founded in 1984, provides a technical forum for discussion of the impact of patent
law and international trade on Thai society.
The CCPN was founded in 1983 to coordinate activities of non-governmental health groups and has successfully overturned some
proposed amendments to patent law on pharmaceuticals. In 1994, CCPN set up the Foundation for Consumers, which has become the
leading consumer organization in Thailand.
The Thai Red Cross AIDS Research Center began operating in December 1989 and plays a leading role with regard to prevention,
counselling, treatment and research on HIV⁄AIDS.
FTA Watch, a coalition of activists from academic institutions, NGOs and peoples’ organizations, was formed in 2003 in response
to government plans to negotiate bilateral FTA negotiations with several countries, most notably the US.
NGOs bringing patients into the movement for access to medicines
The AIDS ACCESS Foundation (ACCESS), established in 1991, works with the media to promote policies to reduce discrimination.
Since 2003, ACCESS has coordinated a Regional HIV⁄AIDS care and treatment training project (developed together with MSF and
TNP+. The ‘We Understand’ Group was founded in January 2004 under the auspices of the AIDS Access Foundation, and is a
collaboration of hospitals, NGOs, PHA groups and volunteers raising public awareness about children and youth living with
HIV⁄AIDS.
MSF, at the request of local NGOs, has been supporting HIV projects in Thailand since 1994. Activities include technical support, lobby
for access to treatment, projects to establish a standard of care at district level (since 1997, in co-operation with the Ofﬁce of Health
Care Reform) and treatment projects with the Thai Ministry of Public Health. MSF, using funds from the 1999 Nobel Peace prize, the
European Commission and Forum Syd, also supports coordination and infrastructure costs of TNP+ and ACCESS, as other
international donors will fund activities but will not support running costs.
The TNP+ was established in 1998 as a response to the isolation of individual PHA groups and their dependency on funding by their
hospital. The founding vision of TNP+ was that PHA should be able to live with dignity and play an active role in society. By 2006 there
were more than 900 PHA groups with 20 000 TNP+ members nationwide.
FTA, free-trade agreement; MSF, Me ´decins Sans Frontie `res; NGO, non-governmental organization; PHA, people with HIV⁄AIDS; TNP+,
Thai Network of People with HIV⁄AIDS; PDA, Population and Community Development Association; CCPN, Coordinating Committee
for Primary Health Care of Thai NGOs.
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policy related to HIV⁄AIDS and in 1990 succeeded in
disbanding a proposed ‘AIDS Bill’ that required mandatory
HIV testing of members of ‘high-risk’ groups (World Bank
2000). In 1991, when more HIV cases were found in the
general population, the government vigorously promoted a
prevention campaign aiming at 100% condom use in
commercial sex establishments (Rojanapithayakorn &
Hanenberg 1996). The campaign is estimated to have
prevented 2 million subsequent infections (UNAIDS 2000).
Nevertheless more than one million people have become
infected since the epidemic began and more than 400 000
have died.
The ﬁrst PHA group was established in 1990 in
Bangkok. With time, more groups were established and
in 1995 their contribution was ofﬁcially recognized by
Ministry of Public Health policy that encouraged the
formation of PHA groups within the hospital system.
By 2006, there were 900 PHA groups with more than
20 000 members (Lyttleton et al. 2007) mainly
supported by government funds channelled through
public hospitals.
Initially, the engagement of PHA groups in HIV care was
focused on social support; advocacy was constrained as
groups were isolated from each other and depended on
funding from their hospital. This changed with the estab-
lishment of the TNP+ in 1998. That year, the Ofﬁce of
Health Care Reform (Table 1) identiﬁed lack of accessible
HIV treatment as a priority (Nitayarumphong 1996), and a
pilot project to deﬁne a standard of treatment for oppor-
tunistic infections at district level was established by the
Ministry of Public Health, MSF and TNP+ (Revenga et al.
2006).
Campaigning for access to antiretroviral treatment
Publicly funded (mono- and dual-) antiretroviral therapy
was ﬁrst made available for limited numbers of patients in
1992 (Revenga et al. 2006). The Ministry of Public Health
began to provide triple antiretroviral therapy in 2000 but
reliance on expensive brand drugs limited beneﬁciaries to
around 1500 people (Phanuphak 2004). Large-scale treat-
ment only became possible later, after the Thai Govern-
ment Pharmaceutical Organisation (GPO) began to
produce a range of generic antiretrovirals.
The Government Pharmaceutical Organisation had
begun research and development of antiretrovirals in 1992,
initially for zidovudine and didanosine. Zidovudine was
launched in 1995, but production of generic didanosine
was blocked when a Thai patent was granted to Bristol-
Myers Squibb in 1998. The patented version was prohi-
bitively expensive and provoked the ﬁrst in a series of
public demonstrations against intellectual property
restrictions to medicines (Limpananont 2002; Wilson
et al.1999; Supakakunti et al. 1999).
At the end of 1999, the GPO submitted a request for a
compulsory license, a request backed by public demon-
strations in which over 300 PHA gathered outside the
Public Health Ministry (Ford et al. 2004). This was the
ﬁrst occasion in Thailand that HIV positive people braved
stigmatization to stage public demonstrations and proved
to be a watershed event in terms of their awareness and
self-conﬁdence. However, under pressure from the US
government (Hecklinger 1999), the Ministry of Public
Health rejected the request. Activists with support from the
Law Society (Table 1) then mounted a legal challenge
against the patent for didanosine, claiming that the patent
had been unlawfully granted (Ford et al. 2004). After
2 years, the court ruled in favour of the plaintiffs, opening
the way for generic production.
Campaigning for universal health care
Prior to 2001, Thailand’s public health system was
accessed through three health insurance systems, but this
led to signiﬁcant exclusion: around three-quarters of the
population lacked insurance (United Nations Development
Programme 2007) and two-thirds of those with health
insurance (those holding low-income health cards) could
not access the beneﬁts to which they were entitled
(Pramualratana & Wibulpolprasert 2002). In 2000, civic
groups drew up a petition demanding that parliament
debate the introduction of universal health insurance
(International Labour Organisation 2008). Under the
Royal Thai Government (1997) Constitution, parliament is
obliged to debate any petition signed by more that 50 000
voters. TNP+ and the Rural Doctors’ Society (Table 1)
with their nationwide networks collected the majority of
more than 60 000 signatures supporting the petition,
forcing a parliamentary debate.
The National Assembly voted against the bill. How-
ever, universal health insurance became a key issue in the
subsequent election campaign and, fulﬁlling its election
promise, the Thai Rak Thai party introduced health
insurance soon after winning the 2001 election, making
Thailand one of the ﬁrst developing countries to provide
universal healthcare coverage to their population. Anti-
retroviral treatment and renal dialysis were initially
excluded from the beneﬁts because of their high cost;
activists were quick to point out that the constitution
prohibits discrimination on account of a particular
disease. In October 2001, the Thai GPO manufactured a
ﬁxed-dose medicine combination, reducing the price of
this regimen from $US 9600 to $US 570⁄patient⁄year.
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(Tantivess & Walt 2008), and the Minister of Public
Health announced that antiretroviral drugs would be
included in this universal access to healthcare policy,
(Phanuphak 2004). However, it took 4 more years of
campaigning before this became a reality (Kiatying-
Angsulee et al. 2006).
Increasing the availability of treatment
While efforts were being made to lower the cost of
treatment, parallel efforts aimed at increasing its avail-
ability. The involvement of PHA in the provision of health
care beyond pilot projects began in May 2000, with a
Buyers’ Club established by TNP+, MSF and ACCESS.
While the public health system was relying mostly on
brand name drugs, TNP+ purchased generic antiretrovirals
from GPO and channelled these drugs to public hospitals
via PHA groups; these drugs were prescribed by govern-
ment doctors, paid for by patients and dispensed by PHA
with supervision from the hospital pharmacists (Kreudhu-
tha et al. 2005; Uppakaew 2008). This programmes
established the principle of partnership at a grassroots level
between NGOs and public healthcare providers, and also
gave GPO its ﬁrst orders for several generic antiretrovirals,
thus kick starting production. The Buyers’ Club was able
to scale down its activities as the government programme
scaled up.
Concurrently, there was a push to increase access to
basic, low-cost medicines for opportunistic infections,
which were poorly available prior to their inclusion in the
national health insurance scheme in 2001. Surveys carried
out by MSF and TNP+ in 2000 found that less than half of
symptomatic PHA received co-trimoxazole prophylaxis;
access to treatment for other opportunistic infections such
as tuberculosis was also limited.
In November 2000, TNP+, MSF and ACCESS launched
a project to increase access to prophylaxis and treatment
for opportunistic infections, referred to as the ‘AIDS can
be treated’ campaign. It was considered essential that
PHA should participate actively in their own treatment
and care if they were to develop the knowledge and
understanding necessary to stop believing that AIDS was
a death sentence. Therefore, the project began by training
PHA from 150 groups across the country to recognize
symptomatic disease and to support each other in
accessing health care. An internal evaluation 2 years after
the project began found that access to correct therapeutic
interventions for the commonest life-threatening oppor-
tunistic infections had increased from less than 50%
before the project began to more than 80% (Kumphitak
et al. 2004).
These experiences showed that with appropriate training
and support PHA could develop a role as partners in
provision of health care. MSF, ACCESS and TNP+
capitalized on the experiences by developing accessible
health education materials and training modules; these
were subsequently used to support the government’s
treatment programme. The chronology of access to HIV
treatment is summarised in Table 2.
PHA support government scale up of antiretroviral
therapy
Collaboration between civic groups and government
expanded considerably in 2002 when Thailand obtained
ﬁnancial support from the Global Fund to Fight AIDS,
Tuberculosis and Malaria for its ambitious scaling up of
antiretroviral treatment. This required NGO participation
at both policy decision and operational levels of the
national HIV programme (Tantivess & Walt 2008). TNP+,
MSF and ACCESS jointly developed a strategy for central
involvement of PHA in the programme. A ‘Comprehensive
and Continuous Care Centre’(CCC Centre) model
(Figure 1) was developed in which PHA activists, working
within the hospital system, provide accessible care and
support, activities that formal health providers have
limited capacity to undertake. (Kumphitak et al. 2004;
Tantivess & Walt 2008).
Most PHA group members in Thailand are farm
labourers, factory workers or unemployed with only
primary education. PHA members working in CCC Cen-
tres, in addition to appropriate training to develop their
knowledge and skills in provision of care, also need
ongoing practical support with such matters as record
keeping, teamwork and coordination with the hospital.
The training and support is provided by TNP+, MSF and
ACCESS.
In addition to providing care and support, the CCC
Centres are an attempt to ensure a central involvement of
grassroots PHA in the government rollout of antiretroviral
therapy. The group must have sought permission from the
hospital director, been assigned a room in the hospital to
do their work, and hospital staff must have agreed that the
PHA can join their HIV care and treatment team. One
activist can normally manage a caseload of 15 to 20 clients.
Activists are expected to recognize common side effects of
antiretroviral drug regimens available in their hospital,
about prevention and treatment of three common oppor-
tunistic infections (TB, Pneumocystis carinii pneumonia
and cryptococcal meningitis) and to be able to provide ‘ﬁrst
aid’ for symptoms such as fever and diarrhoea, and
evaluate treatment adherence. A support team, staffed by
members of TNP+, ACCESS and MSF provides training,
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management, timely submission of reports, record keeping
and problem solving within the CCC Centre teams. One
support team member can manage around 25 CCC
Centres.
This support model is a good investment in terms of
treatment success and life expectancy (Over et al. 2007).
As of mid-2008, antiretroviral treatment was available at
all government hospitals, with 180 000 PHA under treat-
ment. One-third (327) of hospitals had established CCC
centres, each with 3-10 PHA activists. A Ministry of Public
Health⁄World Bank study estimated that systematically
providing PHA peer support in treatment sites throughout
Thailand would increase the cost per life year saved by less
Table 2 Chronology of access to HIV treatment in Thailand
1984 First Thai HIV case
1985 Process patents introduced under United States Government pressure
1988 Increase in numbers of HIV cases in at risk groups (injecting drug user and commercial sex worker)
1990 Bill proposed to introduce mandatory HIV testing for people suspected of belonging to an ‘at risk’ group. Disbanded under
civil society pressure.
First PHA group (Wednesday Friends) established by Thai Red Cross
1991 Sentinel surveillance ﬁrst detected a signiﬁcant level of HIV in the general population (3% amongst army conscripts)
prompting a national campaign promoting 100% condom use in commercial sex establishments
1995 Ministry of Public Health introduces policy to encourage formation of PHA groups within the hospital system
1998 TNP+ established.
MSF, ACCESS and TNP+ begin working together on supporting access to ART, and join the ﬁrst public demonstrations in
Thailand against high prices of ART, organized by the Thai Consumer Foundation
1999 MSF wins Nobel Peace Prize; donates some of the prize money to TNP+ for infrastructure development.
MSF, ACCESS and TNP+ and other civil society organizations support a request by the Thai GPO to the Minister of Public
Health to issue a Compulsory License for didanosine (Request refused.)
2000 MSF start to provide ART in Thailand in one of the organization’s ﬁrst treatment programmes
TNP+, MSF and ACCESS launch campaign to increase access to opportunistic infection medication
ART Buyers Club established
2001 Universal health insurance scheme introduced. ART and treatment for renal failure are initially excluded. Civil Society lobbies
for inclusion of all treatments. NGOs and PHA appointed to various National Health Security Ofﬁce subcommittees.
In October, the GPO manufactures a ﬁxed-dose combination of ARV (GPO-vir). Following NGO lobbying for government
action, minister of Public Health announces that GPO production capacity would be increased and that antiretroviral drugs
would be included in the universal access to healthcare policy.
CCC Centre model, with PHA as co-providers of care, piloted in two public district hospitals, under MSF supervision.
2002 Thai government includes GPO-vir in national ART programme, and scales up treatment nationwide
PHA ﬁle legal claim against Bristol Myers Squibb and the Dept. of IP, contesting the Thai didanosine patent in the IP Court.
The Thai Law Society, the Health and Development Foundation, MSF and ACCESS support this action.
CCC Centre model agreed by TNP+ and ﬁrst 30 centres established in public hospitals, with Global Fund support, to provide
formal role for PHA in health system.
Health and Development Foundation ﬁles pre-grant opposition to zidovudine + lamivudine patent application which is
withdrawn following demonstrations by PHA in Thailand and India.
2003 180 CCC Centres functioning across the country
2004 Didanosine patent overturned in IP court.
2005 ART included in universal health insurance scheme.
2006 TNP+ wins UNAIDS Red Ribbon Award
Zidovudine + lamivudine patent application withdrawn following civil society challenge
Compulsory licence issued for efavirenz
10 000 protestors mobilize against the US–Thai FTA
World Bank study concludes CCC Centre model is cost-effective and recommends compulsory licensing as an option to control
ART costs
National Health Security Ofﬁce agrees to fund an additional 70 CCC Centres, establishing government support for patients as
co-providers of care
2007 Minister of Public Health issues Compulsory License for the antiretroviral drug efavirenz, supported by civil society
2008 Minister of Public Health issues Compulsory License for the antiretroviral drug lopinavir⁄ritonavir, supported by civil society
MSF hands over HIV⁄AIDS care and treatment activities to local partners, but continues advocacy for access to medicines
ART, antiretroviral therapy; CCC, Comprehensive and Continuous Care; FTA, free trade agreement; GPO, Government Pharmaceutical
Organisation; MSF, Me ´decins Sans Frontie `res; NGO, non-governmental organization; PHA, people with HIV⁄AIDS; TNP+, Thai Net-
work of People with HIV⁄AIDS; IP, Intellectual Property.
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et al. 2006).
Initially, the CCC Centres were ﬁnanced by the Global
Fund (95%) and MSF (5%), but an external review of the
health sector response to HIV⁄AIDS in Thailand recom-
mended that community-based organizations should be
more effectively ﬁnanced by domestic sources (Ministry of
Public Health, Thailand & World Health Organisation
2005). From 2006 Global Fund money was matched by the
National Health Security Ofﬁce, which has since commit-
ted to supporting all individual CCC Centre costs from
2009, when the current Global Fund grant expires. But the
National Health Security Ofﬁce has not yet agreed to cover
support costs of the support teams, raising doubts about
how to maintain the quality of the services they provide.
Further efforts to increase access to medicines
Civic groups continued pressing for wider access to
medicines. An important victory was gained in 2006 when
500 people protested outside the ofﬁces of GlaxoSmithKine
in Bangkok, forcing withdrawal of a patent application for
the drug combination of lamivudine + zidovudine (Ford
et al. 2007).
Eight years after the GPO requested a compulsory
licence for didanosine, the Thai government ﬁnally issued
compulsory licenses in 2007 and 2008, including for the
second-line antiretroviral lopinavir–ritonavir. This fol-
lowed a WHO evaluation forecasting that the cost of
antiretroviral therapy with second-line regimens could cost
the country US$ 500 million⁄year by 2020 unless action
was taken against drug prices (Ministry of Public Health,
Thailand & World Health Organisation 2005).
In addition to these actions against speciﬁc patents, civil
society groups have worked to promote public health
within trade negotiations by mobilizing against US trade
pressure for further restrictions via the US–Thai free trade-
agreement (FTA) (Ford et al. 2007). In 2006, nearly
10 000 protesters gathered outside the venue of the free-
trade talks demanding, in line with UN recommendations,
that Thailand should not accept any further reinforcement
of intellectual property protection proposed in the FTA
(Ministry of Public Health et al. 2005). In response, the
Thai Government declared that demands by the United
States for Thailand to tighten up drug patenting were
‘unacceptable’ (Hongthong & Thalang 2006).
Expanding support to other countries⁄diseases
In 2003, ACCESS, MSF and TNP+ set up a project to train
participants from Vietnam, Cambodia and Laos, later
expanding to Nepal, Myanmar and Yunnan (southern
China). While these countries have wide differences in their
level of access to HIV⁄AIDS care and nature of their civil
PHA clients
Nearly all attend the hospital as patients
and most take antiretroviral treatment.
Patients are not obliged to become
clients of the CCC Centre, but most
of them do so. Relatives may also be
CCC Centre clients.  PHA group members
Membership is free and
informal. Relatives or friends
 of PHA are welcome to
become members. Numbers
fluctuate as new members
join or existing members stop
attending.  
PHA activists
3–10 in each CCC, acting
as co-providers of care. 
Figure 1 The CCC centre model.
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lessons learned in Thailand in all of these other countries,
notably the need to develop a broad network of health
workers and NGO staff to ensure ongoing support for
PHA.
In 2007, ACCESS and TNP+ expanded the scope of
their work by helping patients with chronic renal failure
to lobby for access to treatment, and the next year the
National Health Security Ofﬁce began discussing plans to
include renal dialysis in the health insurance scheme.
This reﬂects a broader understanding among both
government and NGO that access to expensive medicines
is not a problem limited to HIV⁄AIDS drugs: the Thai
government has also investigated the possibility to source
generic versions of medicines for cancer, cardiovascular
and neuropathic drugs and antibiotics (Cawthorne et al.
2007).
Conclusions
This paper provides a participant-observers’ perspective of
the role of civil society activism for access to HIV
treatment in Thailand. Such ‘insider’ perspectives carry
the risk of certain biases, in particular in relation to the
issues the researcher focuses on and the framing of
lessons-learnt towards policy-relevant conclusions rather
than generalizable, theoretical themes. We acknowledge
that such biases exist in this account, and do not claim
this to be a historical perspective of all actors involved in
the policy-setting process. Nevertheless, participant
observation holds a critical place in health policy analysis
as it allows for a degree of access to information,
understanding of culture and authenticity that is not
readily available to an external researcher (Walt et al.
2008).
As our account illustrates, PHA have made an essential
contribution to overall provision of treatment and care in
Thailand, to the point that some have concluded that the
scale up and sustainability of antiretroviral therapy (ART)
in Thailand would not have been possible without the
engagement of civil society networks (Tantivess & Walt
2008). The role of these groups has been one of both
co-operation (providing concrete support for patients
and for the health system as a whole) and challenge
(advocating for increased access to treatment as a human
right). Their efforts contributed substantially to the
availability of affordable generic medicines, early treat-
ment for opportunistic infections and an informed and
responsible approach towards antiretroviral treatment that
is supportive of good adherence and treatment success.
Since 1990, the role of PHA in providing peer support
has been increasingly accepted and encouraged in Thai-
land. A change in perception of PHA from ‘passive
receiver’ to ‘co-provider’ of health care came about due to
their own action, with signiﬁcant support from local and
international NGOs. Improved acceptance of and support
for PHA by the healthcare system followed. A few years
ago, health care for PHA was mainly provided by specialist
centres; today, nearly every hospital in Thailand accepts its
responsibility to provide care for PHA and the gap between
doctors and patients has been markedly reduced, with over
one third of all hospitals including a formal role for PHA
through the CCC model. Increased control over their own
health has also brought beneﬁts for PHA in terms of self-
image, conﬁdence, and dignity. Empowerment has come
from the recognition that many of the barriers to care –
lack of access to affordable medicines, lack of national
drug supply and lack of peer support – are barriers they
have been able to overcome themselves. These successes
have ﬁrmly established the role of patients not just as
beneﬁciaries of the health system, but stakeholders in its
development.
With Thailand virtually reaching the goal of universal
access to antiretroviral treatment, the access to medicines
crisis that TNP+ confronted in 1998 is largely resolved. But
access for unregistered groups, principally ethnic minorities
and migrant populations, who account for more than 2
million people in Thailand, remains very limited. Speciﬁc
vulnerabilities make these groups at high risk from
contracting HIV⁄AIDS. Other high-risk groups such as sex
workers and injecting drug users continue to have difﬁculty
accessing the health system (Ainsworth et al. 2003). TNP+
and ACCESS are advocating to extend the reach of the
public ART system to these marginalized groups, and have
negotiated with the Thai government to ensure that a
proportion of the Global Fund grant goes towards
supporting these groups.
Successful campaigning for access to affordable medi-
cines has depended on strong working relationships
between PHA, academics, NGOs, key government ofﬁcials
and journalists who have been willing to take the time to
understand complex issues. This activism has been sup-
portive of, rather than antagonistic towards, government:
pushing the government to increase availability of affor-
dable antiretrovirals, and then providing practical support
to the implementation of treatment programmes when the
medicines become available.
However, with ﬁrst-line treatment available nationwide
and with PHA taking a formal role in policy formulation,
there is no longer a single urgent common cause for which
to ﬁght. Challenges now faced by Thai civic groups, and
which need to be prioritized, include lack of a once-daily
ﬁrst-line regimen, of ﬁxed-dose combinations of ART for
children and of TB medication, of wider access to
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reduction programmes for infecting drug users. Perhaps,
most pressing however, is how to maintain the quality of
CCC Centre services if funding for their support system is
withdrawn.
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